NewsBenzinga美国食品和药物管理局批准 Prime Medicine 公司的 PM647 IND 申请，用于治疗 Alpha-1 抗胰蛋白酶缺乏症的实验性原位 Prime 编辑治疗药物。 美国食品和药物管理局批准 Prime Medicine 公司的 PM647 IND 申请，用于治疗 Alpha-1 抗胰蛋白酶缺乏症的实验性原位 Prime 编辑治疗药物。 Benzinga 2026.09.24 20:02 (GMT+0) Open on Benzinga Other news If Apple Cuts iPhone Units in 2027, This Stock Could Be a Big Loser Trust company AnchorWatch Trust Company launches Bitcoin custody service Wells Fargo Maintains Equal-Weight on PENN Entertainment, Lowers Price Target to $22 HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target Alphabet Stock Rises: What's Going On? $1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today
